Trial Profile
A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors FujiFilm Pharmaceuticals USA
- 21 Oct 2022 Last checked against the ClinicalTrials.gov record.
- 19 Oct 2022 Planned End Date changed from 1 Mar 2023 to 1 Mar 2025.
- 19 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.